David Avigan, MD

Professor of Medicine, Harvard Medical School, Chief of the section of the Hematologic Malignancy and Bone Marrow Transplant Program at Beth Israel Deaconess Medical Center. Director of the Cancer Vaccine Program, Director of the Allogeneic Transplant from Unrelated Donors Program, Director of the Cord Blood Transplant Program.

location_city Beth Israel Deaconess Medical Center

Clinical Expertise

My research interest lies in the field of tumor immunotherapy and its incorporation into bone marrow transplantation. Active projects include the development of dendritic cell tumor fusions to be used as tumor vaccines in a clinical trial for patients with breast cancer now in progression. I have also been exploring the number of immune reconstitution post-transplant and studying the impact of cytokine therapy with IL-12 and GM-CSF on this process. I am currently leading a new trial in the use of post-transplant Her2Neu antibody therapy assessing its impact on persistent residual disease. One group is investigating novel approaches to allogeneic transplantation including the use of non-myeloablative approaches.